Article
Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection
Registro en:
BEZERRA, Cristianne Sousa et al. Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection. Scientifc Reports, v. 12, 1651, p. 1 - 11, 2022.
2045-2322
10.1038/s41598-022-05264-1
Autor
Bezerra, Cristianne Sousa
Portilho, Moyra Machado
Barbosa, Jakeline Ribeiro
Azevedo, Carolina Pimentel de
Mendonça, Ana Carolina da Fonseca
Cruz, José Napoleão Monte da
Frota, Cristiane Cunha
Lago, Bárbara Vieira do
Villar, Lívia Melo
Resumen
Hepatitis B virus (HBV) diagnosis is performed on serum samples, but the access to this diagnosis is
difficult in low-income regions. The use of dried blood spot (DBS) samples does not require special
structure for collection, storage or transport. This study evaluates the use of DBS for detection,
quantification and sequencing of HBV DNA using in-house techniques. Two study groups were
included: 92 HBsAg + individuals and 49 negative controls. Serum and DBS samples were submitted
to quantitative and qualitative in-house PCR for S/pol genes, sequencing and phylogenetic analyses.
Total of 84 serum samples were successfully amplified. Of them, 63 paired DBS were also positive
in qualitative PCR. Qualitative PCR in DBS presented a sensitivity of 75% and specificity of 100%
(Kappa = 0.689). Quantitative PCR in DBS presented a detection limit of 852.5 copies/mL (250 IU/mL),
sensitivity of 77.63% and specificity of 100% (Kappa = 0.731). A total of 63 serum samples and 36 DBS
samples were submitted to sequencing, revealing the circulation of genotypes A (65.08%), D (4.8%),
E (3.2%) and F (27%) with 100% of correspondence between serum and DBS. All sequenced samples
displayed polymorphisms in HBsAg gene. An HIV-coinfected patient presented the rtM204V/I-rtL180M
double resistance mutation in serum and DBS. In conclusion, DBS is an alternative to detect, quantify
and characterize HBV DNA, being a possibility of increasing diagnosis in low-income settings, closing
gaps in HBV control.